Retigeric Acid b exhibits antitumor activity through suppression of nuclear factor-κB signaling in prostate cancer cells in vitro and in vivo

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Liu, Yong Qing ^a,b   Hu, Xiao Yan ^a   Lu, Tao ^c   Cheng, Yan Na ^b   Young, Charles Y F ^d   Yuan, Hui Qing ^a   Lou, Hong Xiang ^b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF UROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL 11 OXO BETA BOSWELLIC ACID; ANTINEOPLASTIC AGENT; BOSWELLIC ACID; CYCLIN D1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; RETIGERIC ACID B; SURVIVIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; I KAPPA B KINASE; TRITERPENE;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GRAFT; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; ACTIVE TRANSPORT; ANIMAL; CELL MOTION; CELL NUCLEUS; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; GENETICS; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; TUMOR CELL LINE;

MUS;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; DOWN-REGULATION; HUMANS; I-KAPPA B KINASE; MALE; MICE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861549757     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038000     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Sriprasad S, Feneley MR, Thompson PM, (2009) History of prostate cancer treatment. Surg Oncol 18: 185-191.
3. Karin M, Lin A, (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227.
4. Suh J, Rabson AB, (2004) NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 91: 100-117.
5. Mauro C, Zazzeroni F, Papa S, Bubici C, Franzoso G, (2009) The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity. Methods Mol Biol 512: 169-207.
6. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, et al. (2002) The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115: 141-151.
7. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, et al. (2003) NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 91: 417-420.
8. Ghosh S, Karin M, (2002) Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl pp. S81-96.
9. Reed JC, (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1: 111-121.
10. Liu H, Liu YQ, Xu AH, Young CY, Yuan HQ, et al. (2010) A novel anticancer agent, retigeric acid B, displays proliferation inhibition, S phase arrest and apoptosis activation in human prostate cancer cells. Chem Biol Interact 188: 598-606.
11. Catz SD, Johnson JL, (2003) BCL-2 in prostate cancer: a minireview. Apoptosis 8: 29-37.
12. Syrovets T, Gschwend JE, Buchele B, Laumonnier Y, Zugmaier W, et al. (2005) Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J Biol Chem 280: 6170-6180.
13. Shishodia S, Majumdar S, Banerjee S, Aggarwal BB, (2003) Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res 63: 4375-4383.
14. Takada Y, Aggarwal BB, (2003) Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J Immunol 171: 3278-3286.
15. Shanmugam MK, Manu KA, Ong TH, Ramachandran L, Surana R, et al. (2011) Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. Int J Cancer 129: 1552-1563.
16. Park B, Sung B, Yadav VR, Cho SG, Liu M, et al. (2011) Acetyl-11-keto-beta-boswellic acid suppresses invasion of pancreatic cancer cells through the downregulation of CXCR4 chemokine receptor expression. Int J Cancer 129: 23-33.
17. Viji V, Helen A, Luxmi VR, (2010) Betulinic acid inhibits endotoxin-stimulated phosphorylation cascade and pro-inflammatory prostaglandin E(2) production in human peripheral blood mononuclear cells. Br J Pharmacol 162: 1291-1303.
18. Kunnumakkara AB, Nair AS, Sung B, Pandey MK, Aggarwal BB, (2009) Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol Cancer Res 7: 118-128.
19. Takada Y, Ichikawa H, Badmaev V, Aggarwal BB, (2006) Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. J Immunol 176: 3127-3140.
20. Chintharlapalli S, Papineni S, Lei P, Pathi S, Safe S, (2011) Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and-independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer 11: 371.
21. Huang CY, Lin CY, Tsai CW, Yin MC, (2011) Inhibition of cell proliferation, invasion and migration by ursolic acid in human lung cancer cell lines. Toxicol In Vitro 25: 1274-1280.
22. Yuan HQ, Kong F, Wang XL, Young CY, Hu XY, et al. (2008) Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem Pharmacol 75: 2112-2121.
23. Zhang AL, Russell PJ, (2006) Paclitaxel suppresses the growth of primary prostate tumours (RM-1) and metastases in the lung in C57BL/6 mice. Cancer Lett 233: 185-191.
24. Thompson TC, Southgate J, Kitchener G, Land H, (1989) Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56: 917-930.
25. Yuan H, Gong A, Young CY, (2005) Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 26: 793-801.
26. Yuan H, Young CY, Tian Y, Liu Z, Zhang M, et al. (2010) Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells. Mol Cell Biochem 339: 253-262.
27. Kang SY, Halvorsen OJ, Gravdal K, Bhattacharya N, Lee JM, et al. (2009) Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci U S A 106: 12115-12120.
28. Kim DK, Yang JS, Maiti K, Hwang JI, Kim K, et al. (2009) A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells. Cancer Res 69: 923-931.
29. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.